CrossRef Text and Data Mining
Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.
Phase 1 Studies of Poziotinib, an Irreversible Pan-HER Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumors
Tae Min Kim, Keun-Wook Lee, Do-Youn Oh, Jong-Seok Lee, Seock-Ah Im, Dong-Wan Kim, Sae-Won Han, Yu Jung Kim, Tae-You Kim, Jee Hyun Kim, Hyesun Han, Woo Ho Kim, Yung-Jue Bang
Cancer Research and Treatment. 2018;50(3):835-842.   Published online 2017 August 29    DOI: https://doi.org/10.4143/crt.2017.303

Excel Download

Phase 1 Studies of Poziotinib, an Irreversible Pan-HER Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumors
Cancer Research and Treatment. 2018;50(3):835-842   Crossref logo
Link1 Link2 Link3

Phase I safety, pharmacokinetic and pharmacodynamic trial of BMS-599626 (AC480), an oral pan-HER receptor tyrosine kinase inhibitor, in patients with advanced solid tumors
Annals of Oncology. 2019;   Crossref logo
Link1

EKB-569, an irreversible inhibitor of the epidermal growth factor receptor: Phase 1 trial results in patients with advanced solid tumors
European Journal of Cancer. 2002;38:S64   Crossref logo
Link1 Link2

Neratinib, an irreversible pan erB receptor tyrosine kinase inhibitor active for advanced HER2+breast cancer
Breast Cancer Research. 2009;11(S1):   Crossref logo
Link1 Link2 Link3

A phase I study of the farnesyltransferase inhibitor Tipifarnib in combination with the epidermal growth factor tyrosine kinase inhibitor Erlotinib in patients with advanced solid tumors
Investigational New Drugs. 2018;   Crossref logo
Link1 Link2 Link3

Safety, pharmacokinetic, and pharmacodynamics of erdafitinib, a pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor, in patients with advanced or refractory solid tumors
Investigational New Drugs. 2017;36(3):424-434   Crossref logo
Link1 Link2 Link3

Why tyrosine kinase inhibitor resistance is common in advanced gastrointestinal stromal tumors
F1000Research. 2013;2:152   Crossref logo
Link1 Link2 Link3

Phase I study of icotinib hydrochloride (BPI-2009H), an oral EGFR tyrosine kinase inhibitor, in patients with advanced NSCLC and other solid tumors
Lung Cancer. 2011;73(2):195-202   Crossref logo
Link1 Link2

396 A Phase I, Dose-finding Study of BI 853520, a Potent and Selective Inhibitor of Protein Tyrosine Kinase 2 in Patients with Advanced or Metastatic Solid Tumors
European Journal of Cancer. 2012;48:120-121   Crossref logo
Link1 Link2

35 POSTER A Phase I trial of a combination of the mToR Inhibitor Everolimus (RAD001) and two schedules of the vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor Vatalanib (PTK787/ZK222584) in patients (pts) with advanced solid tumors
European Journal of Cancer Supplements. 2006;4(12):15   Crossref logo
Link1 Link2

This metadata service is kindly provided by CrossRef from May 29, 2014. Cancer Res Treat has participated in CrossRef Text and Data Mining service since October 29, 2014.